Oral oncology最新文献

{"title":"The role of ctDNA from liquid biopsy in predicting survival outcomes in HPV-negative head and neck cancer: A meta-analysis","authors":"Nivedita Kaorey ,&nbsp;Kyle Dickinson ,&nbsp;Venkata Ramana Agnihotram ,&nbsp;Anthony Zeitouni ,&nbsp;Nader Sadeghi ,&nbsp;Julia V. Burnier","doi":"10.1016/j.oraloncology.2024.107148","DOIUrl":"10.1016/j.oraloncology.2024.107148","url":null,"abstract":"<div><div>The incidence of head and neck cancer (HNC) is on the rise, making it a significant clinical challenge. Human papillomavirus (HPV)-related and HPV-negative HNC exhibit distinct etiopathogenesis and prognoses, requiring targeted approaches for effective management. Conventional tissue biopsies are essential for confirming the diagnosis and locating solid tumors. However, they have limitations in detecting microscopic disease, tracking treatment response, and capturing the dynamic heterogeneity of the mutational profile within the tumor. Liquid biopsy using circulating tumor DNA (ctDNA) analysis has emerged as a promising non-invasive tool to overcome the drawbacks of conventional biopsy for comprehensive molecular profiling.</div><div>This <em>meta</em>-analysis aims to colligate available evidence on the clinical utility of ctDNA analysis in predicting survival outcomes, specifically in HPV-negative HNC. Our systematic search of six electronic databases identified eight publications (N = 886 patients) meeting the inclusion criteria. The included studies reported data from HPV-negative HNC patients, employing ctDNA analysis to report survival outcomes. Our findings reveal a significant association between mutation or methylation in ctDNA and worsened survival outcomes in HPV-negative HNC cases. The presence of ctDNA mutations in <em>TP53</em> and methylation of <em>SEPT9</em> and <em>SHOX2</em> was linked to reduced overall survival, disease-free survival, and progression-free survival. Subgroup analyses demonstrated consistent associations across different survival outcomes, ctDNA detection methods, and blood collection tubes used.</div><div>Our study underscores the need for future research endeavors prioritizing larger, well-designed prospective studies with standardized methodologies to further elucidate the role of ctDNA analysis in guiding personalized treatment approaches and optimizing patient care in this specific HNC cohort.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107148"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histological and genetic criteria define a clinically relevant subgroup of HPV-positive oropharyngeal carcinoma","authors":"Malte Suchan ,&nbsp;Nora Wuerdemann ,&nbsp;Steffen Wagner ,&nbsp;Christine Langer ,&nbsp;Christoph Arens ,&nbsp;Jannik Johannsen ,&nbsp;Johanna Prinz ,&nbsp;Shachi Jenny Sharma ,&nbsp;Arthur Charpentier ,&nbsp;Marcel Mayer ,&nbsp;Charlotte Klasen ,&nbsp;Philipp Zimmermann ,&nbsp;Hans Eckel ,&nbsp;Christopher Kopp ,&nbsp;Christian U. Huebbers ,&nbsp;Sebastian Klein ,&nbsp;Janna Siemanowski ,&nbsp;Jörn Meinel ,&nbsp;Jens Peter Klussmann ,&nbsp;Alexander Quaas ,&nbsp;Christoph Arolt","doi":"10.1016/j.oraloncology.2025.107209","DOIUrl":"10.1016/j.oraloncology.2025.107209","url":null,"abstract":"<div><h3>Introduction</h3><div>Subgroups with a poorer prognosis exist among patients with human papillomavirus positive oropharyngeal squamous cell carcinoma (HPV-positive OPSCC). This study aims to identify histological and genetic differences within HPV-positive OPSCC and correlate these findings with patient outcomes.</div></div><div><h3>Methods</h3><div>The study included 102 OPSCC patients, all tested positive for high-risk HPV DNA and p16INK4a expression. Based on histomorphological classification (HPV Prediction Classification, HPV PC), all cases were categorized as either classic HPV-positive OPSCC (cHPV) or non-classic HPV-positive OPSCC (non-cHPV). Next-generation sequencing (NGS) of selected genes was performed on 55 tumor samples, correlating results with morphological status and survival.</div></div><div><h3>Results</h3><div>Of all cases, 49 % (n = 50/102) were categorized as non-cHPV, histomorphologically resembling HPV-negative OPSCC, and showed significantly poorer overall survival (p = 0.004) and five-year survival rate (5YS: 83.9 % vs. 58.4 %). Multivariate analyses identified HPV PC as an independent prognostic marker (<em>p</em> = 0.027). NGS revealed loss-of-Function (LOF) mutations in TP53 in three non-cHPV samples. Additionally, PIK3CA/PTEN mutations were found in 35.7 % (10/28) of non-cHPV cases. The cumulative burden of gene mutations was higher in the non-cHPV subgroup compared to the cHPV subgroup (<em>n</em> = 53, <em>p</em> = 0.1).</div></div><div><h3>Conclusion</h3><div>HPV PC distinguished two histomorphological subgroups within HPV-positive OPSCCs: cHPV with excellent prognosis and non-cHPV with poorer overall survival. Non-cHPV tumors also exhibited higher overall mutation rates, notably LOF-TP53 and PIK3CA/PTEN mutations. These morphological subtypes, along with their corresponding mutational profiles, warrant further investigation as potential biomarkers for de-escalation intervention trials.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"162 ","pages":"Article 107209"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omitting elective neck dissection in cT1/2N0 oral squamous cell carcinoma with sentinel lymph node metastasis: A prospective study","authors":"Qigen Fang ,&nbsp;Junhui Yuan ,&nbsp;Xu Zhang ,&nbsp;Liyuan Dai ,&nbsp;Ruihua Luo ,&nbsp;Tao Huang","doi":"10.1016/j.oraloncology.2024.107149","DOIUrl":"10.1016/j.oraloncology.2024.107149","url":null,"abstract":"<div><h3>Objective</h3><div>To examine the distribution of non-sentinel lymph nodes (SLNs) and to determine the feasibility of omitting elective neck dissection (END) in cases of cT1/2N0 oral cancer presenting with SLN metastasis.</div></div><div><h3>Methods</h3><div>A prospective cohort of patients with cT1/2N0 oral cancer underwent SLN biopsy using a γ-probe alongside methylene blue staining, followed by subsequent END. The primary outcome variable was non-SLN metastasis, with its predictors evaluated through logistic regression analysis.</div></div><div><h3>Results</h3><div>A total of 200 patients with detectable SLNs were analyzed. Logistic regression revealed a significant odds ratio of 4.28 [95 % confidence interval: 2.11–14.56] for predicting non-SLN metastasis when comparing a depth of invasion greater than 4.0 mm to a DOI of 4.0 mm or less. Among the six cases of non-SLN metastasis, three patients with negative SLN biopsy results exhibited metastasis; one was found in ipsilateral level V and two in contralateral level Ib. In contrast, all three patients with positive SLN biopsy results had a DOI surpassing 4.0 mm, presenting with at least two positive SLNs. Non-SLN metastasis was detected in ipsilateral level III for one patient and at level IV for two others.</div></div><div><h3>Conclusion</h3><div>END may be judiciously omitted in cases where only one positive SLN is identified in early-stage oral cancer with a depth of invasion of ≤ 4.0 mm.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107149"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical treatment of benign parotid gland tumors: From functional surgery to personalized surgery","authors":"Hao Lu ,&nbsp;Shengwen Liu ,&nbsp;Wenya Zhu ,&nbsp;Wanlin Xu ,&nbsp;Wenjun Yang","doi":"10.1016/j.oraloncology.2025.107172","DOIUrl":"10.1016/j.oraloncology.2025.107172","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107172"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143051889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synchronous papillary and medullary thyroid carcinoma with distinct genetic mutations: A case report","authors":"Huanyu Jiang,&nbsp;Lijuan Zhou,&nbsp;Gang Zou,&nbsp;Haidong Zhang,&nbsp;Zhenkun Yu","doi":"10.1016/j.oraloncology.2025.107191","DOIUrl":"10.1016/j.oraloncology.2025.107191","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107191"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Extensive necrosis of the tongue as a very early adverse event of head and neck radiotherapy”","authors":"Lucas Alves da Mota Santana ,&nbsp;Bernardo Ferreira Brasileiro ,&nbsp;Rajiv Gandhi Gopalsamy ,&nbsp;Gina Délia Roque-Torres ,&nbsp;Dalmo Correia-Filho ,&nbsp;Lysandro Pinto Borges ,&nbsp;Cleverson Luciano Trento ,&nbsp;Leandro Napier de Souza","doi":"10.1016/j.oraloncology.2024.107143","DOIUrl":"10.1016/j.oraloncology.2024.107143","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107143"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports","authors":"Shi-Tong Yu ,&nbsp;Da Huang ,&nbsp;Chengfeng Xiong ,&nbsp;Rong Xie ,&nbsp;Jichun Yu","doi":"10.1016/j.oraloncology.2024.107140","DOIUrl":"10.1016/j.oraloncology.2024.107140","url":null,"abstract":"<div><h3>Background</h3><div>Locally advanced papillary thyroid carcinoma (PTC) with <em>RET</em> fusion–positive poses significant challenges for surgical resection due to tumor invasion into critical structures. Neoadjuvant targeted therapies are a promising approach to reduce the tumor burden and improve the resectability. Selperctinib, a <em>RET</em> kinase inhibitor, has been approved for the treatment of advanced or metastatic <em>RET</em>-altered thyroid cancer. However, the efficacy of selperctinib as a neoadjuvant treatment for locally advanced <em>RET</em>-altered thyroid cancer is unclear.</div><div><em>Case Presentation:</em> We report two cases of <em>RET</em> fusion–positive PTC that received neoadjuvant treatment with selperctinib (160 mg twice daily) to reduce the tumor size and enable for radical resection. Tumor sizes were reduced after neoadjuvant treatment with selperctinib. Patients successfully underwent R0 resection with no major surgical complications.</div></div><div><h3>Conclusion</h3><div>Selperctinib isa potential neoadjuvant treatment for PTC with <em>RET</em> fusion–positive.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107140"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapeutic strategies beyond the PD-1/PD-L1 pathway in head and neck squamous cell carcinoma – A scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA","authors":"Ann-Kristin Struckmeier ,&nbsp;Martin Gosau ,&nbsp;Ralf Smeets","doi":"10.1016/j.oraloncology.2024.107145","DOIUrl":"10.1016/j.oraloncology.2024.107145","url":null,"abstract":"<div><div>Head and neck squamous cell carcinoma (HNSCC) poses a considerable challenge due to its high incidence and mortality rates. Immunotherapy targeting PD-(L)1 emerges as a promising approach for HNSCC, as it has the potential to trigger a broad and long-lasting anti-tumor response. Nevertheless, the effectiveness of immunotherapy encounters hurdles, and only a small proportion of patients benefit, with many eventually experiencing relapse. Consequently, there is a pursuit of strategies to enhance overall treatment outcomes. Understanding the mechanisms driving resistance to PD-(L)1 inhibition and devising strategies to overcome these challenges are vital for advancing more effective treatments. Furthermore, gaining insights into the mechanisms of action and safety profiles of novel combination therapies is critical for their successful adoption in clinical practice. As a result, current research is dedicated to investigating various immunotherapeutic agents beyond the PD-1/PD-L1 axis. This review offers a comprehensive overview of the existing immunotherapy strategies in HNSCC with a focus on TIM-3, TIGIT, LAG-3, and VISTA. The aim is to lay a strong foundation for the continual advancement of therapies for HNSCC.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107145"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on, “Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy”","authors":"Shuang Xu,&nbsp;Fengfeng Qin,&nbsp;Wenjian Hu","doi":"10.1016/j.oraloncology.2025.107186","DOIUrl":"10.1016/j.oraloncology.2025.107186","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107186"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma","authors":"J.M. Price ,&nbsp;K. Garcez ,&nbsp;C. Hughes ,&nbsp;L.W. Lee ,&nbsp;H.M. Mistry ,&nbsp;G. Motamedi-Ghahfarokhi ,&nbsp;G.J. Price ,&nbsp;C.M. West ,&nbsp;D.J. Thomson","doi":"10.1016/j.oraloncology.2024.107138","DOIUrl":"10.1016/j.oraloncology.2024.107138","url":null,"abstract":"<div><h3>Introduction</h3><div>Studies reported inferior outcomes when radiotherapy starts &gt;6–8 weeks post-surgery for head and neck squamous cell carcinoma (HNSCC) but are limited due to time variable dichotomization. We assessed the relationship between survival and the time between surgery and radiotherapy as a continuous variable, hypothesising there would be no change in patients’ survival at 6–8 weeks post-surgery.</div></div><div><h3>Methods/Materials</h3><div>Inclusion criteria: patients with HNSCC who underwent surgery and adjuvant (chemo)radiotherapy, Jan 2014-Dec 2020. A sub-cohort included patients with oral cavity squamous cell carcinoma (OCSCC) treated at the same institution, Jan 2016-Dec 2020. The primary endpoint was overall survival (OS); a multivariable Cox model was fitted. For the OCSCC sub-cohort, the endpoint of interest was progression-free survival (PFS); a multivariable competing risk regression model was fitted.</div></div><div><h3>Results</h3><div>386 patients with HNSCC were included (main cohort). The median time between surgery and radiotherapy was 44 days (IQR: 14 days). Plotting time intervals <em>vs</em> log(hazard) did not demonstrate a threshold time where risk of death increases. The time interval between surgery and radiotherapy was not associated with OS (HR 1.00; 95 % CI 0.99–1.02; p = 0.4).</div><div>In the sub-cohort of 208 patients with OCSCC, the time interval between surgery and radiotherapy was not associated with increased risk of cancer <em>vs</em> competing events (HR 1.01; 95 % CI 0.99–1.03; p = 0.5).</div></div><div><h3>Conclusion</h3><div>Increasing time interval between surgery and radiotherapy was not associated with inferior survival outcomes. We suggest patients are considered for radiotherapy &gt;6–8 weeks post-surgery and that no threshold is considered for patient selection.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107138"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}